Federal Circuit affirms invalidity of Lotronex patent

13-11-2015

Roxane Laboratories’s bid to knock out Prometheus Laboratories's patent covering its Lotronex (alosetron) product has been successful after the US Court of Appeals for the Federal Circuit affirmed that it is invalid.


Roxane Laboratories; Prometheus Laboratories; Lotronex; irritable bowel syndrome; US Court of Appeals for the Federal Circuit; generics; ANDA

LSIPR